Drugs / BNT162b2.B.1.351
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05289037 | Mar 2022 → Nov 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04713553 | Feb → Jul 2021 | COVID-19 | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT162b2 (B.1.351) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05289037 ↗ |
| Modality | Vaccine | “2 SARS-CoV-2 RNA vaccine candidates (BNT162b2 and BNT162b2.B.1.351)” NCT04713553 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT04713553 ↗ |